ATE190505T1 - Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung - Google Patents

Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung

Info

Publication number
ATE190505T1
ATE190505T1 AT93907987T AT93907987T ATE190505T1 AT E190505 T1 ATE190505 T1 AT E190505T1 AT 93907987 T AT93907987 T AT 93907987T AT 93907987 T AT93907987 T AT 93907987T AT E190505 T1 ATE190505 T1 AT E190505T1
Authority
AT
Austria
Prior art keywords
ibuprofen
beta
pct
cyclodextrin complex
oral administration
Prior art date
Application number
AT93907987T
Other languages
English (en)
Inventor
Timothy James Grattan
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE190505T1 publication Critical patent/ATE190505T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93907987T 1992-04-10 1993-04-02 Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung ATE190505T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207990A GB9207990D0 (en) 1992-04-10 1992-04-10 Pharmaceutical composition
PCT/GB1993/000702 WO1993020850A1 (en) 1992-04-10 1993-04-02 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE190505T1 true ATE190505T1 (de) 2000-04-15

Family

ID=10713877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907987T ATE190505T1 (de) 1992-04-10 1993-04-02 Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung

Country Status (13)

Country Link
US (1) US5597583A (de)
EP (1) EP0633787B1 (de)
JP (1) JPH07505645A (de)
KR (1) KR950700762A (de)
AT (1) ATE190505T1 (de)
AU (1) AU667095B2 (de)
CA (1) CA2117762A1 (de)
DE (1) DE69328087T2 (de)
ES (1) ES2145772T3 (de)
GB (1) GB9207990D0 (de)
HK (1) HK1012260A1 (de)
NZ (1) NZ251393A (de)
WO (1) WO1993020850A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2531295A (en) * 1994-05-27 1995-12-21 Farmarc Nederland Bv Pharmaceutical composition
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
IT1301966B1 (it) 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
CA2417661A1 (en) * 2000-08-02 2002-02-07 Malope Company Limited Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormality
PT1411899E (pt) * 2001-08-01 2009-04-24 Novartis Ag Composição de mascaramento de sabor
KR100567131B1 (ko) * 2004-01-05 2006-04-05 신일제약주식회사 쓴맛을 차폐한 아르기닌 함유 이부프로펜 경구투여 액상조성물
EP1942877A4 (de) * 2005-11-02 2011-09-14 Teikoku Pharma Usa Inc Organoleptisch annehmbare orale dosierformen von ibuprofen, herstellungsverfahren und anwendung
US20070207206A1 (en) * 2006-03-02 2007-09-06 Rice Bronwyn C Chewable pain formula
WO2007109057A2 (en) * 2006-03-16 2007-09-27 Novartis Ag Solid dosage form containing a taste masked active agent
EP2253329B1 (de) * 2009-04-27 2016-09-21 Laboratorio de Aplicaciones Farmacodinamicas, S.A. Orale Ibuprofenlysinat-Suspension
CN102448499A (zh) * 2009-04-27 2012-05-09 药效学应用实验室股份有限公司 赖氨酸布洛芬口服混悬剂
CN114588107B (zh) * 2022-04-06 2023-04-18 河北一品生物医药有限公司 一种布洛芬赖氨酸盐注射液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
CA1298290C (en) * 1987-01-09 1992-03-31 Herand M. Markarian Solution ibuprofen complexes, compositions and processes for preparing the same
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE4038314A1 (de) * 1990-11-30 1992-06-04 Puetter Medice Chem Pharm Komplexe des aktiven enantiomers des ibuprofens mit cyclodextrin

Also Published As

Publication number Publication date
US5597583A (en) 1997-01-28
AU667095B2 (en) 1996-03-07
DE69328087D1 (de) 2000-04-20
JPH07505645A (ja) 1995-06-22
HK1012260A1 (en) 1999-07-30
CA2117762A1 (en) 1993-10-28
NZ251393A (en) 1996-08-27
AU3898793A (en) 1993-11-18
KR950700762A (ko) 1995-02-20
DE69328087T2 (de) 2000-08-24
GB9207990D0 (en) 1992-05-27
ES2145772T3 (es) 2000-07-16
WO1993020850A1 (en) 1993-10-28
EP0633787B1 (de) 2000-03-15
EP0633787A1 (de) 1995-01-18

Similar Documents

Publication Publication Date Title
DE69328087D1 (de) Verwendung von ibuprofen-beta-cyclodextrin-komplex für die orale verabreichung
DE69115280D1 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
DE69111077D1 (de) Chinazolinderivate um die antitumorwirkung zu verbessern.
ES2113652T3 (es) Pamoato de risperidona.
TR199700844T1 (xx) Pirazolil-Benzoil T�revleri.
AR038430A2 (es) Derivados de parahercuamida b
FI942313A (fi) Välituote atsitromysiiniä varten
IL118167A0 (en) Pyrazolo (1,5a) pyrimidines their preparation and use
FI910653A0 (fi) Synteettiset reseptorianalogit
DE69224295D1 (de) Pestizid und fungizid
MX9401406A (es) Agentes receptores de adenosina selectivos para intensificar el conocimiento.
FI102185B1 (fi) Anionisten diatsoväriaineiden konsentroidut, vesipitoiset liuokset
NO941084L (no) Neuroleptiske 2-substituerte perhydro-1-H-pyrido[1,2-aÅpyraziner
TR26431A (tr) ANIYONIK AZO BOYAR MADDELERININ KONSANTRE, SULU CÖZELTILERININ üRETILMESINE MAHSUS USUL.
FR2734724B1 (fr) Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'alcoolisme
FI934977A0 (fi) Foerfarande foer att reducera elkfoerbrukningen i mikroprocessorbaserade,isynnerhet foer publika telefonstationer avsedda anordningar
ES2128426T3 (es) Retinoides acuosolubles.
MX9201288A (es) Metodo de tratamiento.
ES2098119T3 (es) Nuevas triazoloquinazolinas, su obtencion y empleo.
NO974687D0 (no) Kondenserte <beta>-carboliner
DE69407180D1 (de) Fluoro-nukleosid-reinigung
IT8820800A0 (it) Macchina rimagliatrice rettilinea, in particolare per l'applicazione di bordini ad un capo di abbigliamento.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties